AbbVie denies media reports of talks to buy Revolution Medicines

Core Viewpoint - AbbVie denied being in discussions to acquire Revolution Medicines, countering a report from the Wall Street Journal that suggested advanced talks were underway [1] Group 1: Company Statements - AbbVie stated, "is not in discussions with Revolution Medicines," in response to the acquisition speculation [1] - Revolution Medicines refrained from commenting on the rumors, adhering to its company policy [1] Group 2: Market Reaction - AbbVie shares experienced a decline of 1.3% in extended trading, following a 4% increase during regular trading hours [1] Group 3: Valuation Insights - Revolution Medicines has a market value exceeding $15.4 billion as of its last stock close [1] - The potential acquisition value for Revolution Medicines could be around $20 billion or more, including a typical premium [2]